Ilan Ganot, Alesta Therapeutics CEO (Solid Bio)
January 8, 2025 11:00 AM EST
Financing
Startups

Sol­id Bio's for­mer CEO launch­es new rare dis­ease start­up with €65M Se­ries A

Max Gelman

Senior Editor

A new start­up aim­ing to tack­le rare dis­eases de-stealthed Wednes­day morn­ing with a CEO ex­pe­ri­enced in the space.

Ales­ta Ther­a­peu­tics took the wraps off its …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Aio­los team re­unites with $411M for new biotech with obe­si­ty drugs from Chi­na

Ex­clu­sive: First-of-its-kind in­fant DNA ed­it leads to ap­par­ent cure in dis­ease that set back field 25 years ago

Ver­sant un­veils Light Horse with $62M and a part­ner­ship with No­var­tis

Af­ter lack­lus­ter 2024, bio­phar­ma in­dus­try prays stalled M&A will fi­nal­ly move in­to gear

Coave rais­es €32M Se­ries A de­spite be­ing two years away from the clin­ic

Astel­las stops de­vel­op­ing au­tol­o­gous cell ther­a­py us­ing tech from Xyphos buy­out

A service from the Financial Times